Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ELCC 2025

European Lung Cancer Congress - ELCC

March 26 - 29, 2025

  1. All
  2. Datopotamab Deruxtecan
  3. Durvalumab
  4. Osimertinib
  5. Savolitinib
  6. Savolitinib Osimertinib
  7. Datopotamab Deruxtecan Osimertinib
  8. Datopotamab Deruxtecan Rilvegostomig
  9. Trastuzumab Deruxtecan Rilvegostomig

PDF

Effects of Datopotamab deruxtecan (Dato-DXd) vs. docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic non squamous (NSQ) non-small cell lung cancer (NSCLC): results from TROPION-LUNG01

PDF

Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02.

PDF

Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)

PDF

Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab vs placebo in resected stage IB-IIIA NSCLC

PDF

Global qualitative assessment of factors affecting multidisciplinary team (MDT) care in early-stage NSCLC

PDF

An international multicentre open-label randomised phase III trial evaluating the benefit of adding adjuvant durvalumab after neoadjuvant chemo-immunotherapy in stage IIB-IIIB (N2) resectable NSCLC

PDF

Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): final data extraction from PACIFIC-R

PDF

Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis

PDF

First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE

PPT

Patient-reported outcomes (PROs) from the LAURA study: osimertinib (osi) in patients (pts) with unresectable (UR) EGFR-mutated (EGFRm) stage (stg) III NSCLC without progression after definitive chemoradiation (CRT)

PDF

Long-term survival outcomes with first line (1L) osimertinib monotherapy treatment in U.S. patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations

PDF

Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2

PDF

Real-world patterns of patients with disease progression after first-line osimertinib for EGFRm aNSCLC in China (FLOURISH study)

PDF

Final overall survival and long-term safety outcomes of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 (METex14) mutation: An update from a Phase 3b study

PPT

SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and MET overexpression (OverExp) and/or amplification (AMP) following progressive disease (PD) on osi

PPT

Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

PDF

TROPION-Lung14: A Phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).

PDF

TROPION-Lung15: A Phase 3 study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib.

PDF

TROPION-Lung10: Phase 3 study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig for non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)

PDF

Phase 1b open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig ± carboplatin as first-line treatment for metastatic HER2-overexpressing (HER2-OE) non-small cell lung cancer (NSCLC): DESTINY-Lung03 Part 4

PDF

Effects of Datopotamab deruxtecan (Dato-DXd) vs. docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic non squamous (NSQ) non-small cell lung cancer (NSCLC): results from TROPION-LUNG01

PDF

Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02.

PDF

Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)

PDF

Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab vs placebo in resected stage IB-IIIA NSCLC

PDF

Global qualitative assessment of factors affecting multidisciplinary team (MDT) care in early-stage NSCLC

PDF

An international multicentre open-label randomised phase III trial evaluating the benefit of adding adjuvant durvalumab after neoadjuvant chemo-immunotherapy in stage IIB-IIIB (N2) resectable NSCLC

PDF

Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): final data extraction from PACIFIC-R

PDF

Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis

PDF

First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE

PPT

Patient-reported outcomes (PROs) from the LAURA study: osimertinib (osi) in patients (pts) with unresectable (UR) EGFR-mutated (EGFRm) stage (stg) III NSCLC without progression after definitive chemoradiation (CRT)

PDF

Long-term survival outcomes with first line (1L) osimertinib monotherapy treatment in U.S. patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations

PDF

Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2

PDF

Real-world patterns of patients with disease progression after first-line osimertinib for EGFRm aNSCLC in China (FLOURISH study)

PDF

Final overall survival and long-term safety outcomes of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 (METex14) mutation: An update from a Phase 3b study

PPT

SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and MET overexpression (OverExp) and/or amplification (AMP) following progressive disease (PD) on osi

PPT

Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

PDF

TROPION-Lung14: A Phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).

PDF

TROPION-Lung15: A Phase 3 study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib.

PDF

TROPION-Lung10: Phase 3 study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig for non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)

PDF

Phase 1b open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig ± carboplatin as first-line treatment for metastatic HER2-overexpressing (HER2-OE) non-small cell lung cancer (NSCLC): DESTINY-Lung03 Part 4

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States